GENERAL COMMENTS
In this manuscript, Xa and colleagues report the results of an analysis of a large series of electronic medical records (EMR) of 5.162 patients with myelodysplastic syndrome (MDS) extracted from a US database containing anonymised clinical practice records (GE Centricity EMR Database, GE Healthcare IT, Princeton, NJ). The Authors developed an algorithm to interrogate the database and identify records of interest based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. They then focused the analysis on treatment patterns in patients with MDS , taking into account erythropoiesis stimulating agents (ESA), iron chelation therapy, and disease-modifying (active treatments) including lenalidomide and hypomethylating agents (azacitidine and decitabine). The Authors found that the majority of patients did not receive any of the interrogated treatments (3083/5162, 60%), whereas ESA were the first line and the only treatment in the majority of patients (1.330/5.162, 26% of the whole population and 1.330/2079, 64% of treated patients). Thirty-two percent of patients received disease-modifying treatments at any time. The Authors concluded that a high proportion of patients with MDS do not receive active treatment with approved agents. Overall, data on clinical features and treatment strategies in MDS patients outside the context of clinical trials and reference centre studies are of unquestionable interest, as these cohorts are often variably selected and not entirely representative of the general MDS patient population. In this light, the study by Xa and colleagues is providing useful information; however, the following points deserve critical consideration.
1) Although the analysed dataset derives from a large basis of patient records, it must be considered that these data were not obtained from a population-based registry involving a systematic and pre-specified registration process, and this may have introduced unpredictable selection biases in the population captured in this study. In this light, patients receiving transfusion therapy were markedly underestimated, representing only 9% of this population, and it cannot be deciphered whether the missing information concerned transfusion events or patients requiring transfusions. In addition, the database used in the present study was outside the hospital setting, and the population did not include patients receiving intensive treatments including allogeneic stem cell transplantation. Although this is representing a minor fraction of the general MDS population, it is unquestionably relevant considering the aim of the study to assess the use of disease-modifying therapies.
2) The Authors developed an ad hoc algorithm to identify patients with MDS in the source database using a combination of ICD-9-CM codes and specific procedures (including active therapy, haemoglobin test or bone marrow procedure). The final algorithm implied 2 or more ICD-9-CM codes or 1 ICD-9-CM MDS code and at least one selected procedure. The Authors did not include detailed information on this selection process in the manuscript, and it is unclear (and partly unexpected) why a single ICD-9-CM MDS code was insufficient to select the electronic records related to patients with MDS.
3) The Authors analyse the time in EMR Database, i.e. the time for which patients had data in the system. However, this variable is difficult to interpret as the median time to from date of first entry to date of last entry in the system was apparently 29 days, apparently suggesting that observation time was limited for most of the patients. A more detailed information on the reasons of interruption of the observation/recording is warranted to critically interpret the results of the study.
4) The Authors were unable to collect information of key disease features including blast count, cytogenetic abnormalities and International Prognostic Scoring System (IPSS) risk categories. These variables are extremely relevant to correctly interpreting treatment strategies, as a portion of MDS patients suffer from mild to moderate cytopenia, and may benefit from a treatment strategy aimed at improving cytopenia.
5) Based on the results of this analysis, the Authors argue that a high proportion of patients with MDS in the USA do not receive active therapies approved by regulatory entities and that it is important to improve access to these therapies. This conclusion is partly questionable. In fact, a not negligible proportion of patients with MDS suffer from mild to moderate cytopenia, mainly anemia, and have a life expectancy only marginally reduced compared to an age-matched the general population. These subjects may benefit from a therapy aimed at improving anemia by stimulating the erythropoiesis, and large retrospective analyses consistently suggested that an effective treatment of anemia may result in a survival advantage (Park et al. Blood. 2008; 111:574-82; Jädersten et al. J Clin Oncol. 2008; 26:3607-13) . In the absence of detailed disease profiling, the conclusion that the use of disease-modifying treatment appears to be low is not adequately supported.
6) The following additional points should be considered: -The inclusion in the analysis of iron chelation in the absence of information on transfusion therapy is of limited value.
-The Authors analyse the impact of the available disease-and patient-related variables on the time to active therapy. As a first step, it would be useful to analyse factors affecting the use of active treatments rather than the time to treatment.
VERSION 1 -AUTHOR RESPONSE
Reviewer #1: Thank you for asking me to review this well written paper. Real world experience is important in a disease such as MDS which is rare and a disease of the elderly. I have some areas of comment. Comment 1: Statistics -please can the authors explain what the sensitivity analysis is and why it was chosen. Response to reviewer #1, comment 1 We thank the reviewer for their comment. A sensitivity analysis was performed to examine both the robustness of the results, and the extent to which the results are impacted or changed by the length of time that patients were in the EMR system. The median length of follow-up in this EMR system was short (29 days), and therefore a decision was made to evaluate patients with longer follow-up (≥ 6 months and ≥ 12 months) to examine the extent to which the conclusions of this analysis are affected by the length of follow-up. To clarify this in the manuscript, the text has been revised as follows: As a sensitivity analysis was performed to examine the robustness of the results and the impact of follow-up duration on outcomes. Given that the median duration of follow-up in the EMR system was short (29 days), results were evaluated in 2 cohorts of patients were stratified according to duration with longer follow-up in the EMR system (≥6 months and ≥12 months) to examine whether the duration of follow-up influenced the effects of time on treatment patterns.
Comment 2: Inclusion criteria -appreciate the published abstract from where the criteria originates, but it is unusual! The authors firstly should have a small table of the ICD-9-CM MDS diagnoses and explain to the reader how they are able to have 2 MDS diagnoses. This may perplex the reader without further explanation.
Response to reviewer #1, comment 2 We thank the reviewer for their insightful comment, and agree that the ICD-9-CM codes should be added. For clarification, two different codes were not required for an individual to be included in the analysis; rather two occurrences of an MDS ICD-9-CM code were required. The rationale for this is that a single code is not adequate in an EMR system as a single occurrence of a code can be used to evaluate a patient for MDS, whereas the presence of ≥ 2 ICD-9-CM codes indicates that the patient was diagnosed with this condition at ≥ 2 visits. A table listing ICD-9-CM codes related to MDS diagnosis has been included as Table S1 in the supplementary appendix. The manuscript text has also been clarified as follows:
The initial cohort consisted of 9645 patients with ≥1 MDS-specific International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code (supplementary table S1 ). However, a single occurrence of an MDS-related code in the EMR was deemed inadequate to identify MDS patients; a single occurrence could involve evaluation for MDS without a confirmed diagnosis. Eligibility criteria were modified to limit inclusion to patients with at least 2 occurrences of an MDSrelated code at 2 separate visits (n=563) or ≥1 code and treatment with ≥1 active therapy for MDS (n=1,208), but these approaches were deemed too restrictive. After evaluating different selection approaches, The final algorithm identified patients with MDS by ≥2 ICD-9-CM MDS codes, or ≥1 code AND at least one of the following: ≥1 active therapy for MDS, ≥2 haemoglobin (Hb) tests, or ≥1 bone marrow procedure. Patients with records indicative of non-MDS diagnosis, such as "MDS ruled out", were excluded. The final cohort included a total of 5162 MDS patients (figure 1). Regarding comment 4a, 85 patients had the ICD-9-CM code indicating the presence of the del(5q) abnormality; of these, lenalidomide treatment was received by 51 patients (60%) as stated on page 11, paragraph 4. However, it is not uncommon for investigators to code patients with the del(5q) abnormality as "MDS, not specified".
Regarding third-line treatments (comment 4b), we did not discuss these in detail in this paper, as the majority of patients studied received ≤ 2 therapies -only 236 patients in the cohort received ≥ 2 treatments. Table 1 highlights 28 and 13 patients who received HMA or LEN as third-line therapy.
For added clarity on these points, we have included an additional figure (Figure 2 ) in the manuscript, as shown below: Response to reviewer #1, comment 5 We thank the reviewer for highlighting this error. It has now been corrected.
Comment 6: HMAs -page 11 para 2; can the authors describe first and second line treatments in which HMAs were not used upfront Response to reviewer #1, comment 6 We thank the reviewer for their comment. The discussion of first-and second-line therapies in patients who received HMA therapy second or third is included in discussion of the other treatment groups (LEN/ICT/ESA).
The majority (68%) of patients who received HMA second, received ESA first, as shown in Table 1 . Results for other patients who received HMA second may not be specifically presented but once again, it was not the objective of this manuscript to describe every possible subset of patients.
For added clarity on this point, we have included an additional figure in the manuscript, as shown below: Table 1 due to the complexity of second-and third-line therapies received. In addition, ICT therapy is often given as an adjuvant therapy, alongside other treatments, making the sequence of therapy difficult to ascertain for these patients. To make this clearer, we have moved the footnote of Table 1 into the legend, as below: Comment 8: Page 11 para 4; 'A majority' should read 'The majority' in both places Response to reviewer #1, comment 8 We thank the reviewer for highlighting this. It has now been corrected.
Comment 9: Discussion page 15, para 2; 'remarkable' is too strong, I would prefer 'it is noted that'. Also the manuscript and here particularly need to make the reader aware (many are outside the US) which drugs are approved for which sub groups of MDS and that this is in the US. Are all the drugs in this study being used under their license eg HMAs and LEN? Response to reviewer #1, comment 9 We thank the reviewer for their comment. We have made some changes to the text to soften the language of this section, as shown below. It is remarkable of interest that approved disease-modifying therapies such as LEN and HMAs were used less frequently than ESAs, which are not approved for MDS.
Due to the type of data used for this study, we are unable to confirm whether the drugs in this study were prescribed within their license, and so are not able to include these data.
Comment 10: ESAs are widely used in many countries in lower risk disease. They are well tolerated, cost effective that can lead to transfusion independence and improvement in QOL despite not being approved. The paper is slanted too much towards an opinion about approved drugs being used too infrequently, and in my opinion this should be tempered. Response to reviewer #1, comment 10 We thank the reviewer for their comment. We acknowledge that ESAs are widely used in the United States and in many other countries to treat lower-risk MDS. They are well tolerated, cost effective, and can lead to transfusion independence and improvement in quality. However, ESAs do not treat the actual disease, rather the symptoms.
As such, we have included in the following sentence in the discussion: ESAs only treat the symptoms of anaemia, which is one aspect of this disease and not the actual disease. Comment 11: Page 15 last para; why suddenly is there an outcome included in a small previously published study. I would suggest this sentence is deleted (2nd sentence) as it is irrelevant. Response to reviewer #1, comment 11 We thank the reviewer for this comment. In response to this suggestion, the paragraph referencing this study has now been removed: Another EMR database based on a large community oncology network in the southeastern part of the USA evaluated treatment outcomes in 137 patients with MDS treated with ≥1 cycle of HMAs. . Practice patterns were similar in patients who were in the EMR system for ≥6 months and ≥12 months. Data on treatment outcomes were not available.
Comment 12: Page 16: agree that data on IPSS and CGN not available Para 2; the first sentence does not clarify why it is 'important', either explain further or delete. Response to reviewer #1, comment 12 We thank the reviewer for their comment, and have revised the text as follows, to emphasize why we highlighted the importance of ICT being given in conjunction with other therapies: When considering treatment patterns in this patient group, it is also important to note that ICT is sometimes administered to RBC transfusion-dependent patients, who may be receiving other therapies. When administered in the MDS setting, ICT has not yet been shown in prospective trials to improve survival or to reduce complications of iron overload/transfusional haemosiderosis. Comment 13: Para 3; again an over statement about approved drugs. The study is to look at active therapies overall. Last sentence should be rephrased Response to reviewer #1, comment 13 We thank the reviewer for their comment. We have revised the manuscript as shown below: Despite these limitations, it is clear that active therapies approved for MDS are not used for many patients with MDS in the USA. In contrast, ESAs, which are not approved as a treatment for MDS, were the most commonly used therapy. This suggests that ESAs were used as the primary therapy in patients who had cytopenias other than anaemia. Patients often received ESAs as the first and only therapy for MDS. Given that nearly half of MDS patients have another cytopenia besides anaemia, the apparent use of ESAs in these patients seems inadequate to address the multiple cytopenias. this suggests that ESAs were used as the only therapy in patients who had cytopenias other than anaemia ESAs only treat the symptoms of anaemia, which is one aspect of this disease and not the actual disease. Comparatively, the use of LEN and HMAs, which have been approved for use the treatment of MDS for more than 10 years, for approximately 10 years, appeared to be low is exceptionally low.
Reviewer #2: In this manuscript, Ma and colleagues report the results of an analysis of a large series of electronic medical records (EMR) of 5.162 patients with myelodysplastic syndrome (MDS) extracted from a US database containing anonymized clinical practice records (GE Centricity EMR Database, GE Healthcare IT, Princeton, NJ). The Authors developed an algorithm to interrogate the database and identify records of interest based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. They then focused the analysis on treatment patterns in patients with MDS , taking into account erythropoiesis stimulating agents (ESA), iron chelation therapy, and disease-modifying (active treatments) including lenalidomide and hypomethylating agents (azacitidine and decitabine). The Authors found that the majority of patients did not receive any of the interrogated treatments (3083/5162, 60%), whereas ESA were the first line and the only treatment in the majority of patients (1.330/5.162, 26% of the whole population and 1.330/2079, 64% of treated patients). Thirty-two percent of patients received disease-modifying treatments at any time. The Authors concluded that a high proportion of patients with MDS do not receive active treatment with approved agents.
Overall, data on clinical features and treatment strategies in MDS patients outside the context of clinical trials and reference centre studies are of unquestionable interest, as these cohorts are often variably selected and not entirely representative of the general MDS patient population. In this light, the study by Ma and colleagues is providing useful information; however, the following points deserve critical consideration. Although the analyzed dataset derives from a large basis of patient records, it must be considered that these data were not obtained from a population-based registry involving a systematic and pre-specified registration process, and this may have introduced unpredictable selection biases in the population captured in this study.
In this light, patients receiving transfusion therapy were markedly underestimated, representing only 9% of this population, and it cannot be deciphered whether the missing information concerned transfusion events or patients requiring transfusions. In addition, the database used in the present study was outside the hospital setting, and the population did not include patients receiving intensive treatments including allogeneic stem cell transplantation. Although this is representing a minor fraction of the general MDS population, it is unquestionably relevant considering the aim of the study to assess the use of disease-modifying therapies.
Comment 1: The Authors developed an ad hoc algorithm to identify patients with MDS in the source database using a combination of ICD-9-CM codes and specific procedures (including active therapy, haemoglobin test or bone marrow procedure). The final algorithm implied 2 or more ICD-9-CM codes or 1 ICD-9-CM MDS code and at least one selected procedure.
The Authors did not include detailed information on this selection process in the manuscript, and it is unclear (and partly unexpected) why a single ICD-9-CM MDS code was insufficient to select the electronic records related to patients with MDS. Response to reviewer #2, comment 1 We thank the reviewer for their comment. We realize the manuscript may have been unclear in this respect: an individual did not have to have two different codes to be included in the analysis; however, they did need to have two separate and documented occurrences of an MDS ICD-9-CM code to be considered for inclusion. A single occurrence of an MDS code in an EMR system was not adequate for coding as a single code can be used during evaluation of a patient for MDS, whereas the presence of a second code acts as evidence of a confirmed diagnosis. The presence of ≥ 2 ICD-9-CM codes means that the patient was diagnosed with this condition over ≥ 2 visits. The requirement of the presence of specific procedures-only helped to filter out patients who should not have been included in the final cohort. That this cohort closely mimicked the SEER database, in terms of patient characteristics, serves to validate the appropriateness of the selection procedure. We have updated the manuscript to clarify this point, as shown below: The initial cohort consisted of 9645 patients with ≥1 MDS-specific International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code (supplementary table S1 ). However, a single occurrence of an MDS-related code in the EMR was deemed inadequate to identify MDS patients; a single occurrence could involve evaluation for MDS without a confirmed diagnosis. Eligibility criteria were modified to limit inclusion to patients with at least 2 occurrences of an MDS-related code at 2 separate visits (n=563) or ≥1 code and treatment with ≥1 active therapy for MDS (n=1,208), but these approaches were deemed too restrictive. After evaluating different selection approaches, The final algorithm identified patients with MDS by ≥2 ICD-9-CM MDS codes, or ≥1 code AND at least one of the following: ≥1 active therapy for MDS, ≥2 haemoglobin (Hb) tests, or ≥1 bone marrow procedure. Patients with records indicative of non-MDS diagnosis, such as "MDS ruled out", were excluded. The final cohort included a total of 5162 MDS patients (figure 1).
Comment 2:
The Authors analyze the time in EMR Database, i.e. the time for which patients had data in the system. However, this variable is difficult to interpret as the median time to from date of first entry to date of last entry in the system was apparently 29 days, apparently suggesting that observation time was limited for most of the patients. A more detailed information on the reasons of interruption of the observation/recording is warranted to critically interpret the results of the study. Response to reviewer #2, comment 2 We thank the reviewer for their comment. We are aware of the short median follow-up, and sensitivity analyses were performed to address this issue. Unfortunately the database does not offer information on reason for subject discontinuation.
We have revised the manuscript, by adding the following phrase: Although the database does not provide information on the reason for discontinuation, a short followup time for an individual patient might indicate that they were treated by healthcare professionals outside the EMR network.
Comment 3:
The Authors were unable to collect information of key disease features including blast count, cytogenetic abnormalities and International Prognostic Scoring System (IPSS) risk categories. These variables are extremely relevant to correctly interpreting treatment strategies, as a portion of MDS patients suffer from mild to moderate cytopenia, and may benefit from a treatment strategy aimed at improving cytopenia. Response to reviewer #2, comment 3 We thank the reviewer for their comment. We are aware of this limitation and have included mention of this in the Discussion. Despite the limitations, the overwhelming absence of real-world data in MDS patients, especially elderly MDS patients, makes this analysis important.
Comment 4:
Based on the results of this analysis, the Authors argue that a high proportion of patients with MDS in the USA do not receive active therapies approved by regulatory entities and that it is important to improve access to these therapies. This conclusion is partly questionable. In fact, a not negligible proportion of patients with MDS suffer from mild to moderate cytopenia, mainly anemia, and have a life expectancy only marginally reduced compared to an age-matched the general population. These subjects may benefit from a therapy aimed at improving anemia by stimulating the erythropoiesis, and large retrospective analyses consistently suggested that an effective treatment of anemia may result in a survival advantage (Park et al. Blood. 2008; 111:574-82; Jädersten et al. J Clin Oncol. 2008; 26:3607-13) . In the absence of detailed disease profiling, the conclusion that the use of diseasemodifying treatment appears to be low is not adequately supported. Response to reviewer #2, comment 4 We thank the reviewer for their comment. We accept that patients with MDS and mild to moderate cytopenias may experience improvement in overall survival while being treated with ESAs. However, treating these patients with active therapies that address the disease and not just the symptoms impart greater benefit versus ESAs.
Comment 5:
The following additional points should be considered: -The inclusion in the analysis of iron chelation in the absence of information on transfusion therapy is of limited value. -The Authors analyze the impact of the available disease-and patient-related variables on the time to active therapy. As a first step, it would be useful to analyze factors affecting the use of active treatments rather than the time to treatment. Response to reviewer #2, comment 5 We thank the reviewer for their comment. ICT data were included despite a lack of accompanying transfusion data and an awareness of the limitations of these data. We have revised the results section of the manuscript as shown below: Additional analysis using multivariate logistic regression was performed to identify the predictors for use of active therapies (Y/N). The results of this analysis identified gender, age, presence of comorbidities, time from diagnosis date to analysis cut-off, and Hb level as significantly associated with probability of active treatment, i.e., were consistent with the results of analysis of time to event presented in table 2.
VERSION 2 -REVIEW

REVIEWER
Sally Killick Royal Bournemouth Hospital NHS Foundation Trust, Castle Lane East, Bournemouth, BH7 7DW REVIEW RETURNED 19-Dec-2017
GENERAL COMMENTS
Thank you for addressing the comments, the manuscript is stronger for it.
The revised title could be rephrased
Given that this manuscript has been submitted to a UK journal, I feel strongly that the manuscript should clearly state in the opening paragraph that this manuscript only refers to patient analysis under the remit of the FDA approvals (not Europe -EMEA) and this is not applicable to the UK or Europe. The license for disease modifiers is broader in the USA. The FDA approval details should be included at the beginning of the manuscript as European readers will be less familiar than US readers with these.
In addition:
Page 6: 'The final algorithm identified patients with MDS by ≥ 2 ICD-9-CM MDS codes'; this would read better as: 'ICD-9-CM codes entered into the EMR on ≧2 occasions' as otherwise it still reads as though the patient needs two different ICD-9-CM codes to be included in the study.
With regards the capture of patients with MDS -is there still not a risk that the inclusion of one ICD-9-CM code and two Hb tests may include non-MDS patients, as MDS may well be entertained in any patient who is anaemic?
Is it possible for the authors to compare how many patients in this study received disease modifiers to that which would be reasonably expected in a cohort of US MDS patients from published demographic data? This gives the readers more perspective.
I agree that ESAs are not disease modifying with regards other cytopenias, but we are not given data on the depth of the cytopenias (only the median) in all those receiving an ESA, such that ESA may well be a very reasonable treatment option if the other cytopenias are absent or mild. We can see that the median neutrophil and platelet counts in patients treated with ESA first line are within the normal range and the text tells us that they most commonly had isolated anaemia. However the last but one paragraph suggests that nearly half of patients have another cytopenia, incongruous with the data in Table 1 (as explained above). ESAs are well tolerated and easy to self-deliver at home with few side effects or impact on QOL. These factors are not mentioned by the authors. We must be aware that improvement in QOL is paramount in elderly and often frail patients. Although disease modifiers may well improve QOL by improving the cytopenias, HMAs given SC or IV for instance, have a significant impact on QOL due to the frequency of hospital visits. This is not discussed and should be to give a more balanced view point.
Discussion: para 2 -first sentence regarding patients 'maybe under treated' -without the IPSS-R data this may be an over statement although I do understand the authors thoughts but I think it could be better phrased. For instance: Without the detailed data required for the IPSS-R it is difficult to fully understand why the majority of patients did not receive active therapy, but given the high number, it would suggest that MDS patients maybe under treated which deserves further investigation'. However it must be said without a comparator of what would reasonably expected then this is only an opinion. Also if 59.7% received no treatment for MDS and the transfusion data is not known, is this a correct statement? Transfusion is a treatment, just not a modifying treatment.
Given that ESAs are clearly being used very frequently, could the manuscript suggest further study to look at why physicians are preferring this treatment to understand prescribing habits in more detail, in addition to outcome? 
REVIEWER
GENERAL COMMENTS
Ma and colleagues report the results of an analysis of a large series of electronic medical records (EMR) of 5.162 patients with myelodysplastic syndrome (MDS) extracted from a US database containing anonymized clinical practice records (GE Centricity EMR Database, GE Healthcare IT, Princeton, NJ). The Authors developed an algorithm to interrogate the database and identify records of interest based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. They then focused the analysis on treatment patterns in patients with MDS , taking into account erythropoiesis stimulating agents (ESA), iron chelation therapy, and disease-modifying (active treatments) including lenalidomide and hypomethylating agents (azacitidine and decitabine). The Authors found that the majority of patients did not receive any of the interrogated treatments (60%), whereas ESA were the most common first line therapy (73% of patients receiving any therapy) and the only treatment in the majority of these patients (88%). Thirty-three percent of patients received disease-modifying treatments at any time. The Authors concluded that a high proportion of patients with MDS do not receive active treatment with approved agents.
In this revised manuscript, the Authors partly addressed the critical issues raised by the first version. However, the major limitations of this study are intrinsic in its design and source dataset, and cannot be unambiguously solved. In particular, the following critical points remain unsolved:
1. Although the analyzed dataset derives from a large basis of patient records, it must be considered that these data were not obtained from a population-based registry involving a systematic and pre-specified registration process, and this may have introduced unpredictable selection biases in the study population. In this light, patients receiving transfusion therapy were markedly underestimated, representing only 9% of this population. In addition, the database used in the present study was outside, and the population did not include patients receiving disease-modifying treatments in the hospital setting.
2. The median time to from date of first entry to date of last entry, the time for which patients had data in the system, was 29 days, suggesting that observation time was limited for most of the patients without access to more detailed information on the reasons of interruption of the observation/recording. Although this issue was partly addressed by a sensitivity analysis, this figure raises major concerns on the risk of missing data (e.g. appropriate treatment outside the EMR system) and resultant selection biases.
3. The Authors were unable to collect information of key disease features including blast count, cytogenetic abnormalities and International Prognostic Scoring System (IPSS) risk categories. Although this limitation is acknowledged and discussed in the manuscript, it represents a major weakness, as these variables are extremely relevant to correctly interpreting treatment strategies. In particular, a not negligible portion of MDS patients suffer from mild to moderate cytopenia and may benefit from a treatment strategy aimed at improving cytopenia. In the absence of detailed disease profiling, the assumption that the use of disease-modifying treatment appears to be low is not adequately supported and mainly sustained by an over interpretation of the analysis, resulting in a potentially misleading conclusion.
VERSION 2 -AUTHOR RESPONSE Reviewer #1:
Comment 1:
Response to reviewer #1, comment 1
We thank the reviewer and the journal editor for their feedback on the title revision. Due to the dual nature of this manuscript, which summarised the development of an algorithm to identify patients with MDS from an EMR database and the analysis of treatment patterns within this population, we have revised the title as shown below:
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy Comment 2:
Response to reviewer #1, comment 2
We thank the reviewer for raising this important point, and have revised the introductory paragraphs to clarify that this work was conducted within the context of FDA approvals, as shown below:
In the United States, the treatment of MDS changed between 2004 and 2006, as the US Food and Drug Administration provided regulatory approval for three disease-modifying agents -lenalidomide (LEN) and the hypomethylating agents (HMAs) azacitidine and decitabine.
[3] Initial approvals were based on clinical trials that demonstrated the efficacy and safety of LEN in patients with red blood cell (RBC) transfusion-dependent lower-risk MDS and a deletion of chromosome 5q [del(5q)], [4] and that HMAs induced complete responses and delayed disease progression in some patients with higherrisk MDS. [5, 6] However, as only a select group of patients with MDS is eligible for clinical trials, the results from clinical trials, therefore, may not be translatable to clinical practice in the United States, outside the context of a trial. [7, 8] For example, typically, elderly patients with MDS have significant comorbidities that may exclude them from clinical trial participation and may also limit treatment options in clinical practice.
Comment 3:
Response to reviewer #1, comment 3
We thank the reviewer for the comment and have revised the manuscript accordingly, as shown below:
The final algorithm identified patients with MDS by ICD-9-CM codes entered into the EMR on ≥2 occasions Comment 4:
Response to reviewer #1, comment 4 This is an important point raised by the reviewer. It is a known fact of EMR systems that a single ICD-9-CM code could be used to rule out a diagnosis, and so we included two Hb tests to guard against that. Although it is not possible to guarantee that miscoding did not take place, the reliance on two, consecutive Hb tests reduces the potential for inclusion of non-MDS patients. As mentioned in the main text, the agreement between the population characteristics noted in our study and that reported in the SEER registry supports our selection criteria.
We have revised the discussion to include the following statement:
While we recognise that miscoding is a possibility in any studies using clinical databases, the potential for inclusion of non-MDS patients in this study is minimised through using a highly specific MDS ICD-9-CM code and stringent requirements for Hb tests Comment 5:
Response to reviewer #1, comment 5
This retrospective study was initiated due to the paucity of population-based data on treatment patterns in MDS, and was designed to make best use of the available data sources. We are aware of two ongoing prospective registry studies in this area, one funded by the pharmaceutical industry [Steensma et al. BMC Cancer. 2016 . https://doi.org/10.1186 /s12885-016-2710 , and the other supported by the US National Cancer Institute [The National MDS Natural History Study, https://thenationalmdsstudy.net/, NCT02775383] -both aim to investigate the patterns of treatment within this patient population, but it will be some time before these registries will be able to adequately address these questions. With this in mind, we have added the following statements to the discussion:
Despite potential methodological challenges, we believe this research is meaningful due to the current lack of existing data from a large cohort of patients with MDS in the USA.
Further investigations are ongoing into how treatment patterns affect outcomes in standard clinical practice using data collected outside the context of an interventional clinical trial, including prospective observational studies, such as the Connect® MDS-Acute Myeloid Leukemia Disease Registry (clinicaltrials.gov NCT01688011) [21] , and The National Myelodysplastic Syndromes Natural History Study, sponsored by the National Heart, Lung, and Blood Institute in collaboration with the National Cancer Institute (clinicaltrials.gov NCT02775383).
Comment 6:
Response to reviewer #1, comment 6
We appreciate this comment. First, to clarify the apparent disparity between the text and the data in table 1; table 1 contains baseline values prior to treatment and, as highlighted by the reviewer, provides a median value rather than a measure of the severity of the cytopenias. Relating to the use of ESAs, we agree that these are useful therapies for a subset of patients with MDS. However, many patients included in the study had multiple cytopenias, indicating that the prescription of ESAs may be more appropriate as a first-line treatment option rather than a long-term maintenance therapy. With the availability of other efficacious treatment options for MDS, the prevalent use of ESA monotherapy in patients with multiple cytopenias is something we have reservations about.
Comment 7:
Discussion: para 2 -first sentence regarding patients 'maybe under treated' -without the IPSS-R data this may be an over statement although I do understand the authors thoughts but I think it could be better phrased. For instance: Without the detailed data required for the IPSS-R it is difficult to fully understand why the majority of patients did not receive active therapy, but given the high number, it would suggest that MDS patients maybe under treated which deserves further investigation'. However it must be said without a comparator of what would reasonably be expected then this is only an opinion. Also if 59.7% received no treatment for MDS and the transfusion data is not known, is this a correct statement? Transfusion is a treatment, just not a modifying treatment.
Response to reviewer #1, comment 7
We thank the reviewer for the insightful comment. This comment has prompted us to make a change in the terminology used throughout the manuscript, from "active therapy to "disease-modifying therapy".
We agree with the reviewer that transfusion is an important treatment and regret that we do not have complete data on transfusions in our cohort of MDS patients. On the other hand, the focus of this manuscript is on disease-modifying therapy, not supportive care such as transfusions.
The lack of data on risk stratification is an inherent limitation of our study, linked to the use of EMR data. However, as the MDS patients included in our study are population-based, we would expect them to have a distribution of IPSS-R scores similar to that observed in other large series of MDS patients. Based on this, the rather large percentage of MDS patients not receiving any diseasemodifying therapy is not clinically justifiable.
Comment 8:
Given that ESAs are clearly being used very frequently, could the manuscript suggest further study to look at why physicians are preferring this treatment to understand prescribing habits in more detail, in addition to outcome?
Response to reviewer #1, comment 8
We thank the reviewer for the comment. This study is a retrospective analysis of EMR data; prospective studies investigating the patterns of treatment within this patient population are currently ongoing.
There are a number of studies which examine physician preference within this area, and many concur with our assessment that ESAs are frequently prescribed to patients who may benefit from additional treatments, such as the disease-modifying agents discussed in this study. In particular, studies designed to look at physician attitudes towards the use of ESAs have reported that ESAs are frequently prescribed without proper assessment of serum erythropoietin or risk status (Davidoff et al, 2013) , and the ESA therapy is often short in duration (Davidoff et al, 2013) or discontinued early (Hendrick et al, 2014) . Of note, the FDA issued a safety report for ESAs in 2007, which restricted coverage and reportedly led to a 20-30% decline in ESA use (Hendrick et al, 2014) . Together, this highlights the need for further investigation into the current use of ESAs, and how this may change in the future as the MDS treatment landscape continues to evolve. The manuscript has been updated to include the following statements in the Discussion:
An analysis of Medicare/Medicaid records also suggests a third of patients with MDS do not receive any treatment in the first 6 months post-diagnosis. [17] Of note, the FDA issued a safety report for ESAs in 2007, which restricted coverage and reportedly led to a 13% decline in ESA use in patients with MDS during 2008.[17] This decline was noted from the beginning of August 2007, and so would have had a limited effect on the results of this study, which includes data from patients entered into the EMR database between January 2006 and Feb 2014.
Additionally, there is evidence that physicians may be less likely to prescribe ESAs to older patients due to concerns over cost, and long-term efficacy and safety. [18] Guidelines for the treatment of MDS suggest ESAs have their place in a broad treatment strategy, tailored to the patient [19] ; however, some physicians may not take into account serum erythropoietin levels or risk status when prescribing ESAs [20] , discontinue ESA therapy before the recommended duration [17] , and fail to initiate dose reductions in patients who respond [18] , suggesting ESAs may be inappropriately prescribed in some cases.
Reviewer #2:
Ma and colleagues report the results of an analysis of a large series of electronic medical records (EMR) of 5.162 patients with myelodysplastic syndrome (MDS) extracted from a US database containing anonymized clinical practice records (GE Centricity EMR Database, GE Healthcare IT, Princeton, NJ). The Authors developed an algorithm to interrogate the database and identify records of interest based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. They then focused the analysis on treatment patterns in patients with MDS, taking into account erythropoiesis stimulating agents (ESA), iron chelation therapy, and disease-modifying (active treatments) including lenalidomide and hypomethylating agents (azacitidine and decitabine). The Authors found that the majority of patients did not receive any of the interrogated treatments (60%), whereas ESA were the most common first line therapy (73% of patients receiving any therapy) and the only treatment in the majority of these patients (88%). Thirty-three percent of patients received disease-modifying treatments at any time. The Authors concluded that a high proportion of patients with MDS do not receive active treatment with approved agents.
Although the analyzed dataset derives from a large basis of patient records, it must be considered that these data were not obtained from a population-based registry involving a systematic and prespecified registration process, and this may have introduced unpredictable selection biases in the study population. In this light, patients receiving transfusion therapy were markedly underestimated, representing only 9% of this population. In addition, the database used in the present study was outside, and the population did not include patients receiving disease-modifying treatments in the hospital setting.
Comment 2:
The median time to from date of first entry to date of last entry, the time for which patients had data in the system, was 29 days, suggesting that observation time was limited for most of the patients without access to more detailed information on the reasons of interruption of the observation/recording. Although this issue was partly addressed by a sensitivity analysis, this figure raises major concerns on the risk of missing data (e.g. appropriate treatment outside the EMR system) and resultant selection biases.
Comment 3:
The Authors were unable to collect information of key disease features including blast count, cytogenetic abnormalities and International Prognostic Scoring System (IPSS) risk categories.
Although this limitation is acknowledged and discussed in the manuscript, it represents a major weakness, as these variables are extremely relevant to correctly interpreting treatment strategies. In particular, a not negligible portion of MDS patients suffer from mild to moderate cytopenia and may benefit from a treatment strategy aimed at improving cytopenia. In the absence of detailed disease profiling, the assumption that the use of disease-modifying treatment appears to be low is not adequately supported and mainly sustained by an over interpretation of the analysis, resulting in a potentially misleading conclusion.
Response to reviewer #2
We thank the reviewer for the thoughtful evaluation of our revised manuscript. We acknowledge the inherent limitations of using EMR data; however, we think this study is valuable in terms of providing a first look at the real-world patterns of treatment within this patient population, as prospective studies are still ongoing.
The incomplete data on transfusions reflect the fact that the GE Centricity records only reflect activity in the outpatient office -some hospital activity may be included but only where it was present in physicians' notes. Transfusions are often missing from EMRs as these treatments may be delivered at sites separate from the clinical provider. As this study mostly evaluated therapies given in the GP office setting, and may include some inpatients, our analysis underestimated the frequency of transfusions received by patients, rather than missing patients. Sensitivity analyses were conducted as part of this study to help address the short median duration of follow-up in the EMR database. When we restricted our analyses to patients who had at least 6 or 12 months of follow-up, we observed very similar patterns of disease-modifying therapy, which provided some assurance that the low percentage we observed in the overall cohort is not simply a result of short follow-up. While the possibility of not capturing disease-modifying therapy cannot be completely ruled out, it is important to note that the risk of missing treatments not administered within the setting is low, as the therapies of interest do not require hospitalization for administration.
The lack of data on risk stratification presents a challenge when identifying patients and understanding why they were not prescribed active therapies. While ESAs provide effective treatment for anemia, they may not be the best option for patients with multiple cytopenias. These data highlight the need to continue to improve physician education regarding therapy choice, particularly as the treatment landscape evolves, and new therapies and means of stratifying patients by risk become available.
